This newly patented method utilizes an innovative agglutination-PCR (ADAP) technology, enabling the ultra-sensitive detection of antibodies in extremely low concentrations. This breakthrough facilitates earlier and more precise detection of autoimmune disorders such as T1D, where early identification can dramatically improve patient outcomes.

Peter Robinson, COO of Enable Biosciences, emphasized the importance of this development, stating, “This patent is a testament to our dedication to transforming diagnostic processes. By enabling earlier detection of Type 1 Diabetes, we are not just advancing medical technology but also providing clinical opportunities for better earlier care for those at risk.”

Dr. Jason Tsai, CTO and co-inventor, highlighted the method’s sensitivity, “Our technology can detect antibody concentrations as minute as a few picograms per milliliter. This level of sensitivity is crucial for the early detection of Type 1 Diabetes before it becomes clinically apparent.”